Workflow
AdaptHealth(AHCO) - 2024 Q4 - Annual Results
AHCOAdaptHealth(AHCO)2025-02-25 12:11

Financial Performance - Net revenue for the full year 2024 was 3,261.0million,anincreaseof1.93,261.0 million, an increase of 1.9% compared to 3,200.2 million in 2023[4] - Net income attributable to AdaptHealth Corp. for 2024 was 90.4million,asignificantrecoveryfromanetlossof90.4 million, a significant recovery from a net loss of 678.9 million in 2023[4] - Adjusted EBITDA for the full year 2024 was 688.7million,reflectinga2.7688.7 million, reflecting a 2.7% increase from 670.8 million in 2023[4] - For Q4 2024, net revenue was 856.6million,aslightdecreaseof0.2856.6 million, a slight decrease of 0.2% compared to 858.2 million in Q4 2023[4] - Q4 2024 net income attributable to AdaptHealth Corp. was 50.3million,recoveringfromanetlossof50.3 million, recovering from a net loss of 254.5 million in Q4 2023[4] - Adjusted EBITDA for Q4 2024 was 200.6million,down2.0200.6 million, down 2.0% from 204.6 million in Q4 2023[4] - Net revenue for the three months ended December 31, 2024, was 856,645,aslightdecreaseof0.1856,645, a slight decrease of 0.1% compared to 858,234 in the same period of 2023[21] - Net income attributable to AdaptHealth Corp. for the twelve months ended December 31, 2024, was 90,422,asignificantimprovementfromanetlossof90,422, a significant improvement from a net loss of 678,895 in 2023[32] - Adjusted EBITDA for the twelve months ended December 31, 2024, was 688,657,representinganadjustedEBITDAmarginof21.1688,657, representing an adjusted EBITDA margin of 21.1%, compared to 670,795 and 21.0% in 2023[32] - Operating income for the three months ended December 31, 2024, was 97,667,comparedtoanoperatinglossof97,667, compared to an operating loss of 217,804 in the same period of 2023[21] - Total costs and expenses for the twelve months ended December 31, 2024, were 2,997,243,downfrom2,997,243, down from 3,798,578 in 2023[21] Cash Flow and Financial Position - Cash flow from operations increased to 541.8millionin2024from541.8 million in 2024 from 480.7 million in 2023, while free cash flow rose to 235.8millionfrom235.8 million from 143.2 million[4] - Cash flows from operating activities for the twelve months ended December 31, 2024, increased to 541,839from541,839 from 480,666 in 2023[23] - The company had cash at the end of the period amounting to 109,747,anincreasefrom109,747, an increase from 77,132 at the beginning of the period[27] - Free cash flow for Q4 2024 was 73.1million,comparedto73.1 million, compared to 66.6 million in Q4 2023, representing an increase of 7.2%[34] - For the twelve months ended December 31, 2024, free cash flow totaled 143.2million,adecreasefrom143.2 million, a decrease from 235.8 million in 2023, reflecting a decline of 39.2%[34] - Net cash provided by operating activities for Q4 2024 was 150.4million,downfrom150.4 million, down from 155.3 million in Q4 2023, indicating a decrease of 5.7%[34] Strategic Initiatives and Expenses - AdaptHealth reached a definitive agreement to sell certain incontinence assets in its Wellness at Home segment during Q4 2024[4] - The 2024 period included 2.4millioninchargesrelatedtothechangeinfairvalueofcommonstockissuedfollowingacourtapprovedsecuritiesclassactionlawsuit[35]Consultingexpensesin2024amountedto2.4 million in charges related to the change in fair value of common stock issued following a court-approved securities class action lawsuit[35] - Consulting expenses in 2024 amounted to 13.9 million for systems implementation activities, while 2023 saw 5.6millionforsimilarexpenses,reflectingasignificantincrease[35]Severancechargesin2024were5.6 million for similar expenses, reflecting a significant increase[35] - Severance charges in 2024 were 3.9 million, primarily related to the separation of the former President, compared to 7.1millionin2023,whichincluded7.1 million in 2023, which included 2.9 million for the former CEO's separation[35] - The company incurred 4.5millioninconsultingexpensesassociatedwithassetdispositionsin2024,indicatingastrategicfocusonoptimizingassetmanagement[35]ImpairmentsandInterestExpensesThecompanyreportedagoodwillimpairmentof4.5 million in consulting expenses associated with asset dispositions in 2024, indicating a strategic focus on optimizing asset management[35] Impairments and Interest Expenses - The company reported a goodwill impairment of 13,078 for the twelve months ended December 31, 2024, significantly lower than the 830,787recordedin2023[32]InterestexpenseforthetwelvemonthsendedDecember31,2024,was830,787 recorded in 2023[32] - Interest expense for the twelve months ended December 31, 2024, was 126,668, a slight decrease from $130,299 in 2023[32] - Non-cash goodwill impairment charges were recorded in both years, with 2024 reflecting charges related to the disposition of certain immaterial custom rehab technology assets[35]